BACKGROUND: Increased concentrations of lipoprotein(a) [Lp(a)] have been considered a genetically determined risk factor for coronary artery and cerebrovascular disease. Only 2 small and conflicting studies have investigated the possibility of an association of peripheral arterial disease (PAD) with high serum Lp(a) concentrations and low molecular weight (LMW) phenotypes of apolipoprotein(a) [apo(a)]. METHODS: We measured serum concentrations of Lp(a) and apo(a) phenotypes in 213 patients with symptomatic PAD and 213 controls matched for sex, age (within 2 years), and presence of diabetes. RESULTS: Patients with PAD showed significantly higher median serum concentrations of Lp(a) (76 vs 47 mg/L; P = 0.003) and a higher frequency of LMW apo(a) phenotypes (41% vs 26%; P = 0.002) than controls. After adjustment for several potential confounders, increased Lp(a) concentrations (>195 mg/L, i.e., 75th percentile of the entire study sample) and LMW apo(a) phenotypes were significant predictors of PAD, with odds ratios of 3.73 (95% CI 2.08-6.67; P <0.001) and 2.21 (95% CI 1.33-3.67; P = 0.002), respectively. CONCLUSIONS: In this study sample, both increased serum concentrations of Lp(a) and the presence of LMW apo(a) phenotypes were associated with the presence of symptomatic PAD independent of traditional and nontraditional cardiovascular risk factors. Because PAD is considered an indicator of systemic atherosclerotic disease, our results suggest a possible role of Lp(a) as a genetically determined marker for systemic atherosclerosis.
BACKGROUND: Increased concentrations of lipoprotein(a) [Lp(a)] have been considered a genetically determined risk factor for coronary artery and cerebrovascular disease. Only 2 small and conflicting studies have investigated the possibility of an association of peripheral arterial disease (PAD) with high serum Lp(a) concentrations and low molecular weight (LMW) phenotypes of apolipoprotein(a) [apo(a)]. METHODS: We measured serum concentrations of Lp(a) and apo(a) phenotypes in 213 patients with symptomatic PAD and 213 controls matched for sex, age (within 2 years), and presence of diabetes. RESULTS:Patients with PAD showed significantly higher median serum concentrations of Lp(a) (76 vs 47 mg/L; P = 0.003) and a higher frequency of LMW apo(a) phenotypes (41% vs 26%; P = 0.002) than controls. After adjustment for several potential confounders, increased Lp(a) concentrations (>195 mg/L, i.e., 75th percentile of the entire study sample) and LMW apo(a) phenotypes were significant predictors of PAD, with odds ratios of 3.73 (95% CI 2.08-6.67; P <0.001) and 2.21 (95% CI 1.33-3.67; P = 0.002), respectively. CONCLUSIONS: In this study sample, both increased serum concentrations of Lp(a) and the presence of LMW apo(a) phenotypes were associated with the presence of symptomatic PAD independent of traditional and nontraditional cardiovascular risk factors. Because PAD is considered an indicator of systemic atherosclerotic disease, our results suggest a possible role of Lp(a) as a genetically determined marker for systemic atherosclerosis.
Authors: Christina L Wassel; Claudia Lamina; Vijay Nambi; Stefan Coassin; Kenneth J Mukamal; Santhi K Ganesh; David R Jacobs; Nora Franceschini; George J Papanicolaou; Quince Gibson; Lisa R Yanek; Pim van der Harst; Jane F Ferguson; Dana C Crawford; Lindsay L Waite; Matthew A Allison; Michael H Criqui; Mary M McDermott; Reena Mehra; L Adrienne Cupples; Shih-Jen Hwang; Susan Redline; Robert C Kaplan; Gerardo Heiss; Jerome I Rotter; Eric Boerwinkle; Herman A Taylor; Luis H Eraso; Margot Haun; Mingyao Li; Christa Meisinger; Jeffrey R O'Connell; Alan R Shuldiner; Anne Tybjærg-Hansen; Ruth Frikke-Schmidt; Barbara Kollerits; Barbara Rantner; Benjamin Dieplinger; Marietta Stadler; Thomas Mueller; Meinhard Haltmayer; Peter Klein-Weigel; Monika Summerer; H-Erich Wichmann; Folkert W Asselbergs; Gerjan Navis; Irene Mateo Leach; Kristin Brown-Gentry; Robert Goodloe; Themistocles L Assimes; Diane M Becker; John P Cooke; Devin M Absher; Jeffrey W Olin; Braxton D Mitchell; Muredach P Reilly; Emile R Mohler; Kari E North; Alexander P Reiner; Florian Kronenberg; Joanne M Murabito Journal: Atherosclerosis Date: 2012-02-02 Impact factor: 5.162
Authors: Constantine E Kosmas; Delia Silverio; Andreas Sourlas; Richard Peralta; Peter D Montan; Eliscer Guzman; Mario J Garcia Journal: Ann Transl Med Date: 2019-09
Authors: Monica L Bertoia; Jennifer K Pai; Jun-Hee Lee; Adam Taleb; Michel M Joosten; Murray A Mittleman; Xiaohong Yang; Joseph L Witztum; Eric B Rimm; Sotirios Tsimikas; Kenneth J Mukamal Journal: J Am Coll Cardiol Date: 2013-03-26 Impact factor: 24.094
Authors: Beate R Jaeger; Yvonne Richter; Dorothea Nagel; Franz Heigl; Anja Vogt; Eberhard Roeseler; Klaus Parhofer; Wolfgang Ramlow; Michael Koch; Gerd Utermann; Carlos A Labarrere; Dietrich Seidel Journal: Nat Clin Pract Cardiovasc Med Date: 2009-03
Authors: Eric T Fung; Andrew M Wilson; Fujun Zhang; Nathan Harris; Kim A Edwards; Jeffrey W Olin; John P Cooke Journal: Vasc Med Date: 2008-08 Impact factor: 3.239
Authors: Deepti Gurdasani; Barbara Sjouke; Sotirios Tsimikas; G Kees Hovingh; Robert N Luben; Nicholas W J Wainwright; Cristina Pomilla; Nicholas J Wareham; Kay-Tee Khaw; S Matthijs Boekholdt; Manjinder S Sandhu Journal: Arterioscler Thromb Vasc Biol Date: 2012-10-11 Impact factor: 8.311